Kiniksa Pharmaceuticals International, plc - PE Ratio

The PE Ratio as of August 2026 (TTM) for Kiniksa Pharmaceuticals International, plc (KNSA) is 85.91

According to Kiniksa Pharmaceuticals International, plc’s latest financial reports and current stock price. The company's current PE Ratio is 85.91. This represents a change of 89.15% compared to the average of 45.42 of the last 4 quarters.

Kiniksa Pharmaceuticals International, plc (KNSA) Historical PE Ratio (quarterly & annually)

How has KNSA PE Ratio performed in the past?

The mean historical PE Ratio of Kiniksa Pharmaceuticals International, plc over the last ten years is 5.23. The current 85.91 PE Ratio has changed 164.20% with respect to the historical average. Over the past ten years (40 quarters), KNSA's PE Ratio was at its highest in in the December 2022 quarter at 58.42. The PE Ratio was at its lowest in in the June 2024 quarter at -81.82.

Kiniksa Pharmaceuticals International, plc (KNSA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Kiniksa Pharmaceuticals International, plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kiniksa Pharmaceuticals International, plc (KNSA) Average PE Ratio

How has KNSA PE Ratio performed in the past?

The current PE Ratio of Kiniksa Pharmaceuticals International, plc (KNSA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Kiniksa Pharmaceuticals International, plc (KNSA) PE Ratio vs. Peers

How is KNSA’s PE Ratio compared to its peers?

Kiniksa Pharmaceuticals International, plc’s PE Ratio is greater than IDEAYA Biosciences, Inc. (-18.99), greater than Scholar Rock Holding Corporation (-13.74), greater than Apellis Pharmaceuticals, Inc. (38.71), greater than Veracyte, Inc. (32.88), greater than Catalyst Pharmaceuticals, Inc. (17.49), greater than Amicus Therapeutics, Inc. (-163.73), greater than Adaptive Biotechnologies Corporation (-60.74), greater than Mineralys Therapeutics, Inc. (-13.01), greater than Cidara Therapeutics, Inc. (-34.54), greater than Zai Lab Limited (-11.19),

Build a custom stock screener for Kiniksa Pharmaceuticals International, plc (KNSA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kiniksa Pharmaceuticals International, plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kiniksa Pharmaceuticals International, plc (KNSA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kiniksa Pharmaceuticals International, plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.